Pharmaceutics International Launches New Business Initiative, PII Drug Delivery Solutions

PII, (Pharmaceutics International, Inc.) announced recently the formal launch of a new business initiative, PII Drug Delivery Solutions. In response to demand from its clients for product development tools that meet the challenges of problematic new chemical entities (NCEs) and of product life cycle management (LCM), PII has put together a strategy and dedicated resources focused on drug delivery. This new initiative, named PII Drug Delivery Solutions builds on the PII's proven track record in formulation development and pharmaceutical manufacturing to help its clients bring new products to market with optimized clinical profiles and higher commercial value

Since its inception, PII has built considerable expertise in drug delivery, including conventional controlled release formulation approaches, a portfolio of PII - developed technologies and programs involving third-party platforms - its alliance with Penwest Pharmaceuticals for TIMERx technology being an example.

The strategy for PII Drug Delivery Solutions is to provide dedicated business development, centers of technical excellence, proactive partnering and integrated support from PII core resources. PII believes that its exciting portfolio of in-house and partnered drug delivery technologies can be put to work to assist clients with their product development needs, be they early-stage drug candidate optimization through to the revitalization of a marketed compound.

Steve King, Senior Vice President of PII said, "Our dedicated business development team lead by Robin Mitchell and Susan Wiggins has extensive experience in drug delivery and contract services. We aim to proactively bring creative problem solving solutions and product concepts to our clients. PII already has a very powerful portfolio of technology platforms at our disposal and intends to build on this during 2009." "PII has quietly developed some impressive technologies of its own - nanoparticle formulations and MedCrystalForms' mixed phase co-crystals for enhanced drug bioavailability for example. Through our partnerships with companies like Penwest, we can tackle a broad range of controlled release challenges too", said Robin Mitchell, Senior Director Drug Delivery Solutions adding, "Susan Wiggins and I are very excited about the role that we can play to strengthen our clients' business success in today's very competitive markets".

A new website launched today - www.piidds.com - introduces PII Drug Delivery Solutions. The site will feature PII's growing portfolio of capabilities and resources as it expands.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.